TARA-002 demonstrates high complete response rates in BCG-naïve NMIBC patients, with 72% achieving CR and 50% maintaining it ...

The U.S. Food and Drug Administration has approved Pfizer's Padcev (enfortumab vedotin-ejfv), a Nectin-4 directed ...

TARA-002 achieved a 72% complete response rate in BCG-naive NMIBC patients, with durable responses at 6 and 12 months. The ...

Perioperative enfortumab vedotin and pembrolizumab added to surgery may represent a new standard of care in this population with a high unmet medical need,” said Christof Vulsteke, MD, PhD.

A dysfunction in muscle blood vessels could be to blame for the weak muscles and weight loss that most cancer patients experience, according to a new study from University of Illinois Chicago ...

(THE CONVERSATION) Tumors can destroy the blood vessels of muscles even when the muscles are nowhere close to the tumor. That is the key finding of a new study that my colleagues and I recently ...

(NEW YORK) — It may be the last thing that anyone struggling with breast cancer is thinking about, but it’s important: Get some muscles. A new study published in JAMA Oncology finds that women with ...

Tumour growth is reduced by exercise due to a shift in the body’s metabolism that means muscle cells outcompete cancer cells in the race to get sugar to grow ...

It's well known that exercise is good for health and helps to prevent serious diseases, like cancer and heart disease, along ...

Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive cisplatin after surgery.

The FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph in combination with enfortumab vedotin-ejfv for certain adults with muscle invasive bladder cancer.The indication ...